|本期目录/Table of Contents|

[1]陆泠羽,苏国生,梁娟英,等.高效抗逆转录病毒疗法对艾滋病感染孕妇母婴传播的保护作用[J].慢性病学杂志,2015,(01):12-15.
　LU Ling-yu*,SU Guo-sheng,LIANG Juan-ying,et al.Effectiveness of highly active antiretroviral therapy on prevention of mother-tochild transmission among HIV-positive pregnant women[J].,2015,(01):12-15.
点击复制

高效抗逆转录病毒疗法对艾滋病感染孕妇母婴传播的保护作用(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2015年01期
页码:
12-15
栏目:
论著
出版日期:
2015-01-29

文章信息/Info

Title:
Effectiveness of highly active antiretroviral therapy on prevention of mother-tochild transmission among HIV-positive pregnant women
作者:
陆泠羽1;  苏国生2;  梁娟英2;  罗晓璐2;  韦善求2
1.南丹县妇幼保健院，广西南丹547200；2.南宁市第四人民医院，广西艾滋病临床治疗中心（南宁），南宁530023
Author(s):
LU Ling-yu*;  SU Guo-sheng;  LIANG Juan-ying;  LUO Xiao-lu;  WEI Shan-qiu
*Nandan Maternity and Child Health Hospital, Nandan ,Guangxi 547200, China Corresponding author: SU Guo-sheng, E-mail: suguoshengv@sina.com
关键词:
高效抗逆转录病毒疗法; 艾滋病; CD4 ＋细胞计数; 母婴传播
Keywords:
Highly active antiretroviral therapy (HAAT);  Acquired immune deficiency syndrome (AIDS);  CD4 + cell count;  Mother-to-child transmission (MTCT)
分类号:
R512.91
DOI:
-
摘要:
目的评估高效抗逆转录病毒疗法（HAART） 对预防艾滋病病毒（HIV） 母婴传播的效力。方法 50 例怀孕的艾滋病感染者采用HAART，在怀孕第4 周给予奈韦拉平（NVP） ＋拉米夫定（3TC） ＋齐 多夫定（AZT），随后在分娩时静脉注射NVP，并且产后给婴儿服用NVP 糖浆持续6 周。测定HAART 治疗 前后的CD4 ＋ T 淋巴细胞数和病毒载量。试验数据通过Wilcoxon 配对符号秩和检验进行分析。结果在母亲体 内的CD4 ＋ T 淋巴细胞平均数HAART 治疗后[(495.78±16.68)/ml)]显著高于治疗前[(439.91±17.83)/ml]，差异 有统计学意义(Z=15.564，P<0.01)。在母亲体内的病毒载量HAART 治疗后[(11 572 ± 956)拷贝数/ml]较 治疗前[(17 365 ±1 468)拷贝数/ml]显著降低，差异有统计学意义(Z=11.314，P<0.01)。母亲经过HAART 治疗后超过90.00%(45/50)的婴儿HIV 呈阴性。结论对母亲和孩子的HAART 是防止HIV 母婴传播的有 效方法。
Abstract:
Objective To observe the effect of highly active antiretroviral therapy (HAART) for prevention of mother- to- child transmission (MTCT) among HIV- positive pregnant women. Methods 50 HIV-positive pregnant patients were treated with HAART. They were treated with nevirapine (NVP) + lamivudine (3TC) + zidovudine (AZT) in the fourth week of pregnancy and NVP intravenous injection at delivery day, and the babies were treated with NVP syrup for 6 weeks after birth. CD4 + T lymphocyte count and viral load were measured before and after HAART treatment. Experimental data were analyzed using Wilcoxon matched- pairs signed rank test. Results CD4 + T lymphocyte count of the mothers after HAART [(495.78 ± 16.68)/ml)] were significantly higher than before treatment [(439.91 ± 17.83)/ml], and the difference was statistically significant (Z=15.564,P<0.01). Viral load of the mothers after HAART [(11 572 ± 956) copies/ml] were significantly higher than before treatment [(17 365 ± 1 468) copies/ml], the difference was statistically significant (Z=11.314,P<0.01). 90.00% (45/50) infants were HIV negative because of the HAART treatment. Conclusions Mother and child HAART is an effective way to prevent MTCT of HIV.

参考文献/References:

[1] UNAIDS. UNAIDS Report on the global AIDS epidemic ［R］． Geneva: WHO, 2012.
[2］ Townsend CL, Cortina- Borja M, Peckham CS, et al. Low rates of mother- to- child transmission of HIV following effec? tive pregnancy interventions in the United Kingdom and Ire? land, 2000–2006 ［J］． AIDS, 2008,22(8):973–981.
[3］ Cooper E, Charurat M, Mofenson L, et al. Combination anti? retroviral strategies for the treatment of pregnant HIV- 1- in? fected women and prevention of perinatal HIV- 1 transmission ［J］．Acquir Immune Defic Syndr, 2002,29(5):484–494.
[4］ Dorenbaum A, Cunningham CK, Gelber RD, et al. Twodose intrapartum/newborn nevirapine and standard antiretrovi? ral therapy to reduce perinatal HIV transmission: a randomized trial ［J］． JAMA, 2002,288(2):189–198.
[5］ WHO. Global monitoring framework and strategy for the glob? al plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive ［R］． Gene? va: WHO, 2012.
[6］ WHO, UNAIDS and UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sec? tor. Progress report, 2005, 2006, 2007, 2008, 2009, 2010 ［R］．Geneva: WHO, UNAIDS, UNICEF, 2009.
[7］ UNAIDS & WHO. AIDS Epidemic Update ［R］． Geneva: UNAIDS, 2009.
[8］ NASCOP. Annual Health Sector HIV Report: Progress with the National Health Sector Response National AIDS/STI Control Programme ［R］． Kenya: NASCOP, 2009.
[9］ Nduati R, John G, Mbori- Ngacha D, et al. Effect of breast? feeding and formula feeding on transmission of HIV- 1: a ran? domized clinical trial ［J］． JAMA, 2000,283(9):1167–1174.
[10］ Karon JM, Fleming PL, Steketee RW, et al. HIV in the Unit? ed States at the turn of the century: an epidemic in transition［J］． Am J Public Health, 2001,91(7):1060–1068.
[11］ Wood E, Tyndall MW, Spittal PM, et al. Factors associated with persistent high- risk syringe sharing in the presence of an established needle exchange programme ［J］．AIDS, 2002,16 (6):941–943.
[12］ Gayle HD. Expanding access to HIV prevention ［J］． AIDS Res Ther, 2006,3:2.
[13］ Kerr T, Kaplan K, Suwannawong P, et al. The global fund to fight AIDS, tuberculosis and malaria: funding for unpopular public- health programmes ［J］． Lancet, 2004,364(9428):11 –12.
[14］ Siliciano JD, Siliciano RF. A long- term latent reservoir for HIV- 1: discovery and clinical implications ［J］．J Antimicrob Chemother, 2004,54(1):6–9.
[15］ Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV- 1 transcription in peripheralblood mononuclear cells in patients receiving potent antiretroviral therapy ［J］． N Engl J Med, 1999,340(21):1614–1622.
[16］ Pomerantz R. Residual HIV- 1 disease in the era of highly ac? tive antiretroviral therapy ［J］．N Engl J Med, 1999,340(21): 1672–1674.
[17］ Montaner JS, Harris M, Mo T, et al. Rebound of plasma HIV viral load following prolonged suppression with combination therapy ［J］．AIDS, 1998,12(11):1398–1399.
[18］ Zhang L, Ramratnam B, Tenner- Racz K, et al. Quantifying residual HIV- 1 replication in patients receiving combination antiretroviral therapy ［J］． New Eng J Med, 1999,340(21): 1605–1613.
[19］ NASCOP. Guidelines for prevention of mother to child trans? mission (PMTCT) of HIV/AIDS in Kenya fourth edition ［R］． Kenya: Ministry of Health, 2012.
[20］ Taylor GP, Clayden P, Dhar J, et al. British HIV association guidelines for the management of HIV infection in pregnant women 2012 ［J］． HIV Med, 2012,13(2):87–157.
[21］ Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV- infected adults: lessons from the implementation of viral load- driven antiretro? viral therapy ［J］． AIDS, 1998,12(2):279–284.
[22］ Biesma RG, Brugha R, Harmer A, et al. The effects of global health initiatives on country health systems: a review of the evi? dence from HIV/AIDS control ［J］． Health Policy Plan, 2009,24(4):239–252.
[23］ Cu- Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV- 1 RNA ［J］． AIDS, 2000,14(4):415–421.
[24］ Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV- 1 in semen ［J］． AIDS, 1997,11(10):1249–1254.
[25］ Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1 ［J］．New Eng J Med, 2000,342(13):921–929.
[26］ Musicco M, Lazzarin A, Nicolosi A, et al. For the Italian study group on HIV heterosexual transmission. Antiretroviral treat? ment of men infected with human immunodefi ciency virus type 1 reduces the incidence of heterosexual transmission ［J］． Arch Intern Med, 1994,154(17):1971–1976.
[27］ Study EC. Mother- to- child transmission of HIV infection in the era of highly active antiretroviral therapy ［J］． Clin Infect Dis, 2005,40(3):458–465.

备注/Memo

备注/Memo:
基金项目：南宁市科学研究与技术开发计划项目（20143154）；广西壮族自治区卫生厅自筹经费科研课题（Z2014574； Z2010166） 作者简介：陆泠羽，本科，主管技师，主要从事新生儿疾病的实验室诊断工作 通信作者：苏国生，E-mail: suguoshengv@sina.com
更新日期/Last Update: 2015-01-15